DU
RXRX icon

Delphia (USA)’s Recursion Pharmaceuticals RXRX Stock Holding History

Delphia (USA)’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-10,212
Closed -$76.3K – 162
2023
Q2 		$76.3K Sell
10,212
-16,258
-61% -$114K 0.12% 202
2023
Q1 		$177K Buy
+26,470
New +$210K 0.22% 201
2022
Q3 		– Sell
-18,281
Closed -$149K – 402
2022
Q2 		$149K Buy
+18,281
New +$122K 0.1% 311

Other funds holding RXRX

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
KA
Kinnevik AB Stockholm, Sweden $65.6M AUM 25.95% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
DCI
Data Collective IV Palo Alto, California $55.9M AUM 49.14% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Delphia (USA)'s RXRX Position: Q3 2023 in Review

Delphia (USA) sold out of Recursion Pharmaceuticals (RXRX) in Q3 2023, closing a stake of 10,212 shares — an estimated $76.3K sold.

Delphia (USA) first reported a position in RXRX in Q2 2022 and held it in 3 quarters. The position peaked at $177K in Q1 2023. 192 funds tracked by Wall St. Rank hold RXRX as of Q3 2023.

  • Delphia (USA) reported no remaining Recursion Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Delphia (USA) sold 10,212 Recursion Pharmaceuticals shares in Q3 2023, an estimated $76.3K.
  • Delphia (USA) first reported a position in Recursion Pharmaceuticals in Q2 2022 and held it in 3 quarters.
  • Delphia (USA)'s Recursion Pharmaceuticals position peaked at $177K in Q1 2023.
  • 192 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q3 2023.

Based on Delphia (USA)'s 13F filing for Q3 2023, filed 15 Nov 2023.